Comparison of Two sTRAtegies For the Non-Invasive Diagnosis of advanCed Liver Fibrosis in NAFLD

NCT04681573

Status	RECRUITING
Phase	Not Applicable
Sponsor	University Hospital, Angers
Enrollment	1,045 participants

Key Eligibility Criteria

Inclusion (8)

- Presence of NAFLD as defined by :
- The presence of liver steatosis as assessed by ultrasonography (bright liver) or magnetic resonance imaging/spectroscopy (fat fraction \>5.6%) or Controlled Attenuation Parameter (e248 dB/m)
- The absence of steatosis-inducing drugs (systemic corticosteroids, methotrexate, amiodarone, tamoxifen)
- The absence of excessive alcohol consumption (\<210 g/week in men or \<140 g/week in women)
- The absence of other causes of chronic liver disease (chronic viral hepatitis B or C, hemochromatosis, auto-immune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, Wilson disease alpha-1-antitrypsin deficiency).

... and 3 more (see full listing online)

Exclusion (9)

- Decompensated cirrhosis (ascites, variceal bleeding, hepatic encephalopathy, liver failure, hepato-renal syndrome)
- Hepatocellular carcinoma
- Inability to safely undergo liver biopsy
- Participation in other intervention study with drug protocol treatment in progress at the time of inclusion or within one month prior to inclusion in the study.
- Pregnant, breastfeeding or parturient woman

... and 4 more (see full listing online)

Locations (20 total)

University Hospital of Angers, Angers, France
University Hospital of Besançon, Besançon, France
Avicenne Hospital (Greater Paris University Hospitals), Bobigny, France
... and 17 more locations